Testing effectiveness (Phase 2)UnknownNCT05732129
What this trial is testing
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
Who this might be right for
Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
Fudan University 29